Dyslipidemia risk among antipsychotics is described as which pattern?

Dyslipidemia risk among antipsychotics is described as which pattern?

• A. Higher with SGAs than FGAs
• B. Lower risk with SGAs than FGAs, and within FGAs, low-potency have the lowest risk while high-potency have the highest
• C. No risk with any antipsychotics
• D. Only related to age

Answer: (B)

Dyslipidemia risk with antipsychotics is tied to how the drug influences metabolic parameters like weight, insulin sensitivity, and lipid processing. The pattern reflected here is that second-generation antipsychotics tend to have a comparatively lower impact on lipid levels than first-generation agents. Among the older, first-generation drugs, the risk generally increases with potency: lower-potency agents are associated with the least dyslipidemia risk, while higher-potency agents carry more risk. This framework helps explain why clinicians weigh a drug’s generational class and potency when considering metabolic side effects and why monitoring lipid profiles is important across antipsychotic therapy, with particular attention to agents known for greater metabolic effects.

Dyslipidemia risk with antipsychotics is tied to how the drug influences metabolic parameters like weight, insulin sensitivity, and lipid processing. The pattern reflected here is that second-generation antipsychotics tend to have a comparatively lower impact on lipid levels than first-generation agents. Among the older, first-generation drugs, the risk generally increases with potency: lower-potency agents are associated with the least dyslipidemia risk, while higher-potency agents carry more risk. This framework helps explain why clinicians weigh a drug’s generational class and potency when considering metabolic side effects and why monitoring lipid profiles is important across antipsychotic therapy, with particular attention to agents known for greater metabolic effects.